Bac·trim (b k tr m) A trademark for a mixture of sulfamethoxazole and trimethoprim. |
Bactrim,
sulfamethoxazole-trimethoprim (co-trimoxazole)
Apo-Sulfatrim (CA), Apo-Sulfatrim DS (CA), Bactrim, Bactrim DS, Fectrim (UK), Novo-Trimel (CA), Novo-Trimel DS (CA), Nu-Cotrimox (CA), Nu-Cotrimox DS (CA), Septra, Septra DS, Septrin (UK), Sulfatrim, Trisulfa (CA), Trisulfa DS (CA), Trisulfa S Suspension (CA)
Pharmacologic class: Sulfonamide
Therapeutic class: Anti-infective
Pregnancy risk category C
Action
Sulfamethoxazole inhibits bacterial synthesis of dihydrofolic acid by competing with para-aminobenzoic acid (PABA). Trimethoprim inhibits enzymes of folic acid pathways.
Availability
Injection: 80 mg/ml sulfamethoxazole and 16 mg/ml trimethoprim
Suspension: 200 mg sulfamethoxazole and 40 mg trimethoprim/5 ml
Tablets: 400 mg sulfamethoxazole and 80 mg trimethoprim (single strength); 800 mg sulfamethoxazole and 160 mg trimethoprim (double strength)
⊘Indications and dosages
➣ Urinary tract infections caused by susceptible organisms
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days
Children ages 2 months and older: 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim P.O. q 12 hours for 10 days
➣ Severe urinary tract infections caused by susceptible organisms
Adults and children ages 2 months and older: 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for up to 14 days
➣ Shigellosis caused by susceptible strains of Shigella flexneri or Shigella sonnei
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days. Alternatively, 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for 5 days.
Children ages 2 months and older: 40 mg/kg (sulfamethoxazole) and 8 mg/kg (trimethoprim) P.O. q 12 hours for 5 days. Alternatively, 8 to 10 mg/kg (based on trimethoprim component) I.V. q 6, 8, or 12 hours for up to 5 days.
➣ Acute exacerbation of chronic bronchitis caused by susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension P.O. q 12 hours for 10 to 14 days
➣Pneumocystis jiroveci pneumonia
Adults and children older than 2 months: 75 to 100 mg/kg (sulfamethoxazole) and 15 to 20 mg/kg (trimethoprim) P.O. daily in equally divided doses q 6 hours for 14 to 21 days. Alternatively, 15 to 20 mg/kg (based on trimethoprim component) I.V. q 6 to 8 hours for up to 14 days.
➣ Prophylaxis of P. jiroveci pneumonia
Adults: One double-strength tablet P.O. daily
Children ages 2 months and older: 750 mg/m2 (sulfamethoxazole) and 150 mg/m2 (trimethoprim) P.O. b.i.d. in equally divided doses on 3 consecutive days each week. Total dosage should not exceed 1,600 mg sulfamethoxazole and 320 mg trimethoprim.
➣ Traveler's diarrhea caused by susceptible strains of enterotoxigenic Escherichia coli
Adults: One double-strength tablet or two single-strength tablets or 20 ml suspension q 12 hours for 5 days
➣ Acute otitis media caused by susceptible strains of S. pneumoniae or H. influenzae
Children ages 2 months and older: 40 mg/kg sulfamethoxazole and 8 mg/kg trimethoprim P.O. q 12 hours for 10 days
Off-label uses
• Granuloma inguinale
• Toxoplasmic encephalitis (as primary prophylaxis)
Dosage adjustment
• Renal impairment
Contraindications
• Hypersensitivity to sulfonamides, trimethoprim, sulfonylureas, thiazides, or loop diuretics
• Porphyria
• Marked renal or hepatic impairment
• Megaloblastic anemia caused by folate deficiency
• Pregnancy at term or when premature birth is possible
• Infants younger than 2 months (except in P. jiroveci pneumonia prophylaxis)
Precautions
Use cautiously in:
• urinary obstruction, renal or hepatic disease, bronchial asthma, G6PD deficiency, group A beta-hemolytic streptococcal infection, blood dyscrasias
• history of multiple allergies
• elderly patients
• pregnant (before term) or breastfeeding patients
• children.
Administration
• Dilute each 5 ml of I.V. drug in 125 ml of dextrose 5% in water.
• Infuse I.V. over 60 to 90 minutes. Avoid rapid infusion.
• Don't mix with other drugs or solutions. Don't refrigerate. Use within 6 hours after dilution.
| Route | Onset | Peak | Duration |
| P.O. | Rapid | 1-4 hr | Unknown |
| I.V. | Rapid | 1 hr | Unknown |
Adverse reactions
CNS: headache, depression, hallucinations, insomnia, drowsiness, fatigue, apathy, anxiety, ataxia, vertigo, polyneuritis, peripheral neuropathy, seizures
CV: allergic myocarditis or pericarditis
EENT: periorbital edema, optic neuritis, transient myopia, tinnitus
GI: nausea, vomiting, abdominal pain, stomatitis, glossitis, dry mouth, pancreatitis, anorexia, pseudomembranous colitis
GU: hematuria, proteinuria, crystalluria, toxic nephrosis with oliguria and anuria, renal failure
Hematologic: megaloblastic anemia, agranulocytosis, aplastic anemia, thrombocytopenia, leukopenia, hemolytic anemia
Hepatic: jaundice, hepatitis, hepatocellular necrosis
Respiratory: shortness of breath, pleuritis, allergic pneumonitis, pulmonary infiltrates, fibrosing alveolitis
Skin: generalized skin eruption, urticaria, pruritus, alopecia, local irritation, exfoliative dermatitis, photosensitivity reaction, epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome
Other: irritation at I.V. site, chills, drug fever, hypersensitivity reactions including anaphylaxis, serum sickness, lupus-like syndrome
Interactions
Drug-drug . Cyclosporine: increased nephrotoxicity
Dapsone: increased blood levels of both drugs
Hydantoins, zidovudine: increased blood levels of these drugs
Indomethacin, probenecid: increased sulfamethoxazole blood level
Methotrexate: increased risk of bone marrow suppression
Oral anticoagulants: increased anticoagulant effect
PABA, PABA-derived local anesthetics: inhibited sulfamethoxazole action
Sulfonylureas: increased risk of hypoglycemia
Thiazide diuretics: increased thrombocytopenic effects
Uricosuric drugs: increased uricosuric effects
Drug-diagnostic tests. Bilirubin, blood urea nitrogen, creatinine, eosinophils, transaminases: increased levels
Granulocytes, hemoglobin, platelets, white blood cells: decreased levels
Urine glucose tests: false-positive results
Drug-herbs. Dong quai, St. John's wort: increased risk of photosensitivity
Drug-behaviors. Sun exposure: increased risk of photosensitivity
Patient monitoring
☞ Monitor CBC with white cell differential. Watch for evidence of blood dyscrasias.
☞ Stay alert for erythema multiforme. Report early signs before condition can progress to Stevens-Johnson syndrome.
• Monitor patient for signs and symptoms of superinfection, including fever, tachycardia, and chills.
☞ Monitor liver function tests and assess for evidence of hepatitis.
☞ Check kidney function tests weekly. Evaluate patient's fluid intake, urine output, and urine pH. Report hematuria, oliguria, or anuria right away.
• Monitor neurologic status. Report seizures, hallucinations, or depression.
Patient teaching
• Advise patient to take on regular schedule as prescribed, along with a full glass of water. Tell him to drink plenty of fluids to minimize crystal formation in urine.
• If suspension is prescribed, make sure patient has a specially marked measuring spoon or other device so he can measure doses accurately.
• Instruct patient to complete full course of treatment even if he starts to feel better.
☞ Teach patient to recognize and immediately report signs and symptoms of hypersensitivity, especially rash.
☞ Inform patient that drug can cause blood disorders, GI and liver problems, serious skin reactions, and other infections. Describe key warning signs and symptoms (easy bruising or bleeding, severe diarrhea, unusual tiredness, yellowing of skin or eyes, sore throat, rash, cough, mouth sores, fever). Tell him to report these right away.
☞ Urge patient to promptly report scant or bloody urine or inability to urinate.
• Tell patient to contact prescriber if he develops depression.
• Teach patient effective ways to counteract photosensitivity effect. Advise him that dong quai and St. John's wort increase phototoxicity risk and should be avoided during therapy.
• Advise female patient to inform prescriber if she is pregnant. Tell her not to take drug near term.
• Caution female patient not to breastfeed, because she could pass drug effects to infant.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, herbs, and behaviors mentioned above.
Bactrim®
How to thank TFD for its existence? Tell a friend about us, add a link to this page, add the site to iGoogle, or visit webmaster's page for free fun content.
| ?Page tools | ||
|---|---|---|
|